芪倍合剂与双歧杆菌四联活菌片联用治疗肠易激综合征临床研究

Clinical Research on Qibei Mixture with Bifidobacterium Tetravaccine Tablets Treatment of Irritable Bowel Syndrome

目的:观察芪倍合剂与四联活菌联用治疗肠易激综合征的临床疗效。方法:将90例肠易激综合征(IBS)患者,按随机数字表法分为芪倍合剂组、四联活菌组、联合治疗组,每组各30例。芪倍合剂组采用芪倍合剂治疗;四联活菌组采用双歧杆菌四联活菌片治疗;联合治疗组采用芪倍合剂与四联活菌联合治疗。三组均以4周为1个疗程。结果:芪倍合剂组有效率为80.00%,四联活菌组有效率为73.33%,联合治疗组有效率为93.33%,联合治疗组有效率明显高于单一用药组,差异有统计学意义(P<0.05),三组均无明显不良反应。结论:联合应用芪倍合剂和双歧杆菌四联活菌片是治疗IBS的一种安全有效的方法。

Objective：To investigate the clinical curative effect of Qibei Mixture with Bifidobacterium Tetravaccine Tablets treatment of irritable bowel syndrome. Methods ：90 patients with irritable bowel syndrome （IBS） patients were randomly divided into the Qibei Mixture group,the Bifidobacterium Tetravaccine group,the combination group,each of 30 cases. The Qibei Mixture group was treated with Qibei Mixture, the Bifidobacterium Tetravaccine group was treated with Bifidobacterium Tetravaccine Tablets,the combination group was treated with Qibei Mixture and Bifidobacterium Tetravaceine Tablets. 4 weeks for a course of treatment for the three groups. Results：The effective rate of Qibei Mixture group was 80.00% , the Bifidobaeterium Tetravaecine group was 73.33 % , and the combination group was 93.33 % , and the effective rate of the combination group was obviously higher than that of the single drug group, and the difference was statistically significant （P 〈 0.05 ）. There was no significant adverse reactions of the three groups. Conclusion： Qibei Mixture with Bifidobacterium Tetravaccine Tablets is a safe and effective method for the treatment of IBS.